PRINCETON, N.J., June 9
/PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC
Bulletin Board: DORB), a late-stage biopharmaceutical company,
announced today that it has...
EWING, NJ -- (Marketwire) -- 01/20/09 -- DOR BioPharma, Inc. (DOR or
the Company) (OTCBB: DORB) announced today that it has engaged Amper,
Politziner & Mattia, LLP
(Amper) to serve...
EWING, NJ -- (Marketwire) -- 08/15/08 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the
"Company") today announced its financial results for the second quarter
ended June 30,...
EWING, NJ -- (Marketwire) -- 08/07/08 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the
"Company"), a late-stage biopharmaceutical company, announced today that
one of its academic...
DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the
"Company"), a late-stage biopharmaceutical company, announced today that it
has entered into a one-year exclusive option with the...
#7: DORB News CORRECTING and REPLACING DOR BioPharma Awarded Two Grants Totaling $5.3 Million to Advance Ricin Toxin and Botulinum Toxin Vaccine Programs
MIAMI--(BUSINESS WIRE)--Reissuing release to correct ticker symbol for searching purposes.
The corrected release reads:
DOR BIOPHARMA AWARDED TWO GRANTS TOTALING...
NEW YORK--(BUSINESS WIRE)--Wall Street Advisor has initiated coverage of DOR BioPharma, Inc.
(OTCBB:DORB) with a Speculative Buy recommendation. The report may be
found at...
#5: DORB News DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD; First GI-Directed Therapy to Treat the Most Common Life Threatening Complication of Hematopoietic Stem Cell Transplantation
MIAMI--(BUSINESS WIRE)--Sept. 22, 2006--DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), announced today that it has submitted in the Electronic Common Technical Document format a New...
#4: DORB News DOR BioPharma Announces the Appointment of Christopher J. Schaber, Ph.D. as its new President and Chief Executive Officer and Changes in its Board of Directors
MIAMI--(BUSINESS WIRE)--Aug. 30, 2006--DOR BioPharma, Inc. (OTCBB:DORB) ("DOR" or the "Company"), a biopharmaceutical company addressing life-threatening side effects of cancer and cancer...
MIAMI--(BUSINESS WIRE)--Aug. 14, 2006--DOR BioPharma, Inc. (OTCBB:DORB) ("DOR" or the "Company"), announced today its financial results for the second quarter ended June 30, 2006. Revenue for the...
MIAMI--(BUSINESS WIRE)--July 6, 2006--DOR BioPharma, Inc. (OTCBB:DORB) ("DOR" or the "Company"), announced today that it has successfully completed its cGMP (current Good Manufacturing Practices)...
MIAMI--(BUSINESS WIRE)--June 30, 2006--Reissuing release to correct ticker symbol for searching purposes. The corrected release reads: DOR BIOPHARMA PROVIDES REGULATORY UPDATE ON ORBEC DOR...
